Co-pay programs spur new offering

Pharma's increased investment in co-pay card programs has led research firm TargetRx to launch a product offering more insight into their adoption and use.

The new product couples the firm's attitudinal and prescribing databases with a physician-segmentation tool to “hone in on and predict which types of physicians marketers should focus on and which messages should be emphasized,” as well as enable marketers to adjust their programs during implementation, according to a statement.

As an adherence tool, co-pay card programs are becoming more common amid the rise of competition among branded drugs and pharma's decreased DTC spending.

“By understanding which physicians are most motivated to recommend co-pay cards to patients, we can help make sure these programs are successful, and even more importantly, ensure that these incentives are making it into the hands of the patients who need it most,” said Craig Scott, TargetRx CEO.


You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.